Literature DB >> 22855396

Daily quality control in CD3+ and CD4+ T cell estimation by the FACSCount system at a tertiary care center in south India.

Veena V Ramalingam1, Monika Mani, Vijayanand C Sundaresan, Ramesh J Karunaiya, Jaiprasath Sachithanandham, Rajesh Kannangai.   

Abstract

CD4(+) T cell count estimations are subject to high variations; hence, in this study, the previous day's tested samples were included routinely as the internal quality controls. The percentages of variation of the 2-day values were analyzed for 280 observations and the mean variation for CD4(+) and CD3(+) T cell counts ranged from 5.21% to 9.66%. This method is a good internal quality control (IQC) procedure for the estimation of CD3(+) and CD4(+) T cell counts in resource-poor settings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855396      PMCID: PMC3485896          DOI: 10.1128/CVI.00246-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  10 in total

1.  Absolute CD4+ T-lymphocyte and CD34+ stem cell counts by single-platform flow cytometry: the way forward.

Authors:  D Barnett; V Granger; L Whitby; I Storie; J T Reilly
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

2.  Evaluation of a dry format reagent for CD4+ and CD8+ T-cell enumeration with FACSCount and Guava PCA [corrected].

Authors:  J Sachithanandham; K Solomon; S Prasannakumar; G Nithyandham; R Kannangai
Journal:  Indian J Med Microbiol       Date:  2011 Oct-Dec       Impact factor: 0.985

Review 3.  Uses of CD4-lymphocyte count in AIDS treatment decisions.

Authors:  V De Gruttola; R Gelman; S Lagakos
Journal:  Infect Agents Dis       Date:  1993-10

Review 4.  Difficulties in precise quantitation of CD4+ T lymphocytes for clinical trials: a review.

Authors:  D T Fei; H Paxton; A B Chen
Journal:  Biologicals       Date:  1993-09       Impact factor: 1.856

5.  Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.

Authors:  A I Goldman; B P Carlin; L R Crane; C Launer; J A Korvick; L Deyton; D I Abrams
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-02-01

6.  Grading of laboratories on CD4+ T-lymphocyte evaluations based on acceptable data boundaries defined by the measurement error.

Authors:  Annalisa Kunkl; Domenico Risso; Maria Paola Terranova; Mauro Girotto; Bruno Brando; Lorenzo Mortara; Pasquale Bruno Lantieri
Journal:  Cytometry       Date:  2002-04-15

Review 7.  CD4+ T-lymphocyte measures in the treatment of individuals infected with human immunodeficiency virus type 1. A review for clinical practitioners.

Authors:  B J Turner; F M Hecht; R B Ismail
Journal:  Arch Intern Med       Date:  1994-07-25

8.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

Authors:  Jonathan E Kaplan; Henry Masur; King K Holmes
Journal:  MMWR Recomm Rep       Date:  2002-06-14

9.  Three-colour flow cytometric immunophenotyping in HIV-patients; comparison to dual-colour protocols.

Authors:  S T Lillevang; U Sprogøe-Jakobsen; B Simonsen; T Kristensen
Journal:  Scand J Immunol       Date:  1995-02       Impact factor: 3.487

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

  10 in total
  1 in total

1.  Duplicate analysis method: a cheaper alternative to commercial IQC materials in limited resource settings for monitoring CD4 testing.

Authors:  Ashwini Shete; Dharmesh P Singh; Bharati Mahajan; Amol Kokare; Ramesh Paranjape; Madhuri Thakar
Journal:  AIDS Res Ther       Date:  2015-08-14       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.